Rationale: Integrins cooperate with growth factor receptors to promote downstream signaling for cell proliferation and migration. However, the mechanism of receptor activation is still unknown. Objective: To analyze the mechanism of phosphorylation of the vascular endothelial growth factor receptor (VEGFR)-3 by cell adhesion. Src as tyrosine 830, 833, 853, 1063, 1333, and 1337 , demonstrating that integrin-mediated receptor phosphorylation induces a phosphorylation pattern that is distinct from that induced by growth factors. Furthermore, pull-down assays show that integrin-mediated VEGFR-3 phosphorylation activates the recruitment to the receptor of the adaptor proteins CRKI/II and SHC inducing activation of JNK. Conclusions: These data suggest that cell adhesion to extracellular matrix induces a downstream signaling using the tyrosine kinase receptor VEGFR-3 as scaffold.
C rosstalk between integrins and growth factor receptors plays an important role in vascular development and its maintenance. Several examples demonstrated that crosstalk between integrins and tyrosine kinase receptors is required for growth factor-induced biological processes to ensure cell growth, survival, and differentiation in normal and pathological processes. 1 The angiogenic processes require the coordination of signals from the extracellular environment to activates specific tyrosine kinase receptors and integrins. 1, 2 Integrins associating with growth factor receptors regulate the capacity of the integrin/receptor complexes to propagate downstream signals. 3, 4 Integrin-dependent activation of receptor tyrosine kinases is a general mechanism to enhance growth factor signals, the recruitment of transducing proteins to membrane cytoskeletal complexes as well as nuclear responses. This cooperation has been shown for several signaling pathways including insulin, epidermal growth factor (EGF), platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor (VEGF) signaling. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Integrins are able to trigger ligand-independent EGF receptor autophosphorylation leading to activation of the downstream pathway. 16 Integrins, c-Src, p130Cas and EGF receptor associate in a macromolecular complex on the cell membrane and integrin-dependent adhesion induces phosphorylation of specific tyrosine residues of EGF receptor, distinct from those obtained by the soluble ligand EGF. 11, 19 A large body of evidence demonstrates that the angiogenic process is initiated by mitogenic signals induced by growth factors such as VEGF and the interplay between the tyrosine kinase receptors and integrins expressed on endothelial cells plays a critical role in this process. 20, 21 VEGF stimulation of endothelial cells induces the formation of a complex between vascular endothelial growth factor receptor (VEGFR)-2 and ␣v␤3 that induces a synergistic response crucial for angiogenesis. 8, [21] [22] [23] [24] [25] [26] VEGFR-3 (Flt-4) plays a role in vasculogenesis and angiogenesis. [27] [28] [29] [30] [31] [32] [33] VEGFR-3 localizes in caveolae and activates cell cycle progression, survival, and migration by the activation of MAPK pathways. 34 -36 VEGFR-3, in contrast to its highly related endothelial receptor VEGFR-2 (which, after VEGF stimulation, forms a complex with integrin ␤3 subunit 8, 20, 21, 24, 25, 37 ), associates selectively with integrin ␤1. 10, 12 Cell attachment to fibronectin or collagen induces the phosphorylation of VEGFR-3 in the absence of a ligand and significantly enhances the phosphorylation of the receptor induced by its ligand. 10, 12 However, the mechanism of integrin activation of VEGFR-3 has not been clarified.
Here, we demonstrate that collagen I-induced activation of VEGFR-3 is independent from the intrinsic catalytic activity of the receptor but it is a direct target of c-Src. c-Src phosphorylates VEGFR-3 at specific tyrosine residues with a pattern of phosphorylation that is distinct from the pattern induced by the ligand. Cell adhesion induces the phosphorylation of the tyrosine residues 1063 and 1337, which are known binding sites for CRKI/II and SHC. Pull-down assays demonstrated that integrin-mediated receptor phosphorylation induces the recruitment of CRKI/II and SHC second messengers to the receptor suggesting that the integrin/receptor complex can activate growth and survival signaling in the absence of activation of the intrinsic receptor kinase by its cognate ligands.
Methods

Cell Lines, Cultures, and Assays
Details of primary endothelial cells, cell lines, growing conditions, inductions with extracellular matrix (ECM) proteins or VEGF-D,
Figure 1. VEGFR-3 phosphorylation by cell adhesion to the ECM does not require the receptor kinase activity. A,
HUVECs were plated on type I collagen (4 g/cm 2 ), and VEGFR-3 phosphorylation was analyzed at the times indicated. Total cell extracts were immunoprecipitated with anti-P-tyrosine and revealed with anti-VEGFR-3. B, HUVECs were plated on type I collagen at increasing concentration for 15 minutes and VEGFR-3 phosphorylation was analyzed as described previously. C, HEK 293 cells transfected with pcDNA3 vectors expressing VEGFR-3 wild-type (WT) or VEGFR-3 kinase dead mutant (KD) were treated for 30 minutes with conditioned media from 293-FT expressing VEGF-D. D, HEK 293 cells transfected with pcDNA3 vectors expressing VEGFR-3 WT and KD were plated on collagen I for 15 minutes. Total cell extracts were immunoprecipitated with anti-P-tyrosine and revealed with anti-VEGFR-3. E, HUVECs transduced with PINCO retroviral vector expressing the chimeric receptor EGFR-VEGFR3 (E-R3) WT or KD as indicated were treated with 1 ng/mL EGF for 10 minutes. Immunoprecipitates were performed with anti-VEGFR-3 antibody and detected with anti-P-tyrosine or anti-VEGFR-3 antibodies. F, HUVECs transduced with chimeric receptor E-R3 WT or KD as indicated were plated on collagen I for 15 minutes. Cell lysates were immunoprecipitated with anti-P-tyrosine antibody and revealed with anti-VEGFR-3. G, HUVECs transduced with chimeric receptor E-R3 WT were pretreated for 30 minutes with 5 mol/L MAZ 51 before treatment with 1 ng/mL EGF for 10 minutes. Total cell extracts were immunoprecipitated with anti-VEGFR-3 antibody and detected with anti-P-tyrosine and anti-VEGFR-3 antibodies. H, HUVECs transduced with chimeric receptor E-R3 WT were pretreated for 30 minutes with 5 mol/L MAZ51 before plating for 15 minutes on collagen I. Immunoprecipitates were performed with anti-P-tyrosine and revealed with anti-VEGFR-3 antibody. 
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Constructs expressing human VEGFR-3, E-R3 chimeric receptors, GST-SH2 of CRK, and GST-PTB of Shc were previously described. 35 Small hairpin (sh)RNA expressing lentiviral vectors were described. 38 Details of immunoblotting, immunoprecipitation procedures, and antibodies are provided in the Online Data Supplement. c-Src kinase assay, mass spectrometry analysis and GST pulldown assay are described in the Online Data Supplement.
Results
Integrin-Dependent VEGFR-3 Phosphorylation Does Not Require the Intrinsic Kinase Activity of VEGFR-3
It has been recently demonstrated that VEGFR-3 is highly expressed in angiogenic sprouts and specific inhibition of VEGFR-3 in vascular endothelial cells inhibits angiogenesis in vivo. 31 Because the interplay between ECM and endothelial cells plays a key role in angiogenesis, we here analyzed VEGFR-3 activation by type I collagen in human umbilical vein endothelial cells (HUVECs). We observed that plating HUVECs on type I collagen induces a transient VEGFR-3 phosphorylation with peak at 15 minutes ( Figure 1A and 1B; Online Figure I ). To verify whether the receptor phosphorylation by cell adhesion is independent from the intrinsic kinase activity of the receptor, we generated a kinase dead VEGFR-3 receptor by site directed mutagenesis of tyrosine 1068 (VGFR-3-Y1068F) as this residue substitution inactivates the receptor kinase. 35 The wild-type and the VEGFR-3 kinase dead receptor were transiently transfected in HEK 293 cells as these cells express integrin ␤1 (Online Figure II) . Analysis of the receptor phosphorylation revealed, as expected, phosphorylation of the wild-type receptor following cell treatment with VEGF-D, whereas VEGFR-3-Y1068F mutant resulted inactive ( Figure 1C and Online Figure I ). In contrast, both, the wild-type as well as the kinase inactive receptor, were phosphorylated by plating cells on type I collagen ( Figure 1D and Online Figure I) . To analyze the cell adhesion-dependent receptor phosphorylation in endothelial cells we used a chimeric receptor containing the extracellular domain of the EGF receptor fused to the transmembrane and cytoplasmic domain of VEGFR-3, either wild-type (E-R3) or mutant (E-R3KD), carrying the Y1068F substitution. In serum-free starved HUVEC treatment with EGF ligand failed to activate E-R3KD ( Figure 1E ). Conversely, adhesion of HUVECs on collagen I-coated dishes resulted in an evident phosphorylation of both E-R3 wild-type and the kinase dead receptor ( Figure 1F ).
Furthermore, cell adhesion in the presence of MAZ 51, a drug that specifically inhibits VEGFR-3 kinase activity, inhibited VEGFR-3 autophosphorylation in response to growth factor activation, whereas it had no effect on adhesion-dependent receptor phosphorylation ( Figure 1G and 1H).
Taken together these results demonstrate that cell adhesion induces VEGFR-3 phosphorylation independently from the receptor kinase activity. Integrin ␤1 and c-Src form a complex with VEGFR-3. A, HUVECs were plated on type I collagen or gelatin, and total cell extracts were immunoprecipitated with anti-integrin ␤1 antibodies as indicated and revealed with the anti-VEGFR-3 and anti-integrin ␤1 N20. B, Total cell extracts of HUVECs plated on type I collagen were immunoprecipitated with anti-VEGFR-3 and revealed with anti-integrin ␤1. C, Immunoprecipitation of total HUVEC extracts plated on fibronectin with anti-integrin ␤3 and revealed with anti-VEGFR-2, VEGFR-3, and antiintegrin ␤3 as indicated. D, Integrin ␤1 coimmunoprecipitated with VEGFR-3 and c-Src in cell extracts from HEK 293 plated on type I collagen transiently transfected with a pcDNA3 vector expressing VEGFR-3 either wild-type (WT) or KD. Immunoprecipitates were performed with anti-␤1-integrin and detected by Western blot with anti-VEGFR-3, anti-c-Src, and anti-␤1integrin. E, Integrin ␤1 coimmunoprecipitated with E-R3 and c-Src in cell extracts from HUVECs plated on type I collagen transduced with chimeric receptor E-R3 either WT and KD. Cells extracts were immunoprecipitated with anti-␤1-integrin and detected with anti-VEGFR-3, anti-c-Src, and anti-␤1-integrin antibodies. F, In vitro kinase assay using recombinant c-Src to phosphorylate E-R3 KD immunoprecipitated from total cell lysates of HUVECs transduced with E-R3 KD. Sp3 was used as a control of c-Src specific phosphorylation. Immunoprecipitates were performed with anti-VEGFR-3 antibody, subjected to kinase assay with active c-Src and detected with anti-P-tyrosine and anti-VEGFR-3 antibodies.
Integrin-Mediated Adhesion Triggers c-Src to Phosphorylate VEGFR-3
The above results establish that collagen I-mediated VEGFR-3 phosphorylation is dissociated from the intrinsic catalytic activity of the receptor, suggesting that a specific activating complex is induced by integrin engagement to ECM. As shown in Figure 2A , VEGFR-3 was always associated with integrin ␤1 because on type I collagen, it Peptide sequences are indicated along with the position of pYsites, the indicated peptide scores, observed mass-to-charge ratios (m/z), charge state (z), and mass error. The isobaric phosphopeptides GGQVFpYNSEYGELSEPSEEDHCSPSAR and GGQVFYNSEpY-GELSEPSEEDHCSPSAR, which differ only for the position of the phosphoryl moiety, are chromatographically indistinguishable, and hence the resulting MS/MS spectrum is the combination of both contributions. The same can be said for the couple of isomeric phosphopeptides TGYLSIIMDPGEVPLEEQCEpYLSYDASQWEFPR and TGYLSIIMDPGEVPLEEQCEYLSpYDASQWEFPR. coimmunoprecipitated with both an antibody that immunoprecipitates total integrin ␤1 (N20) and an antibody that specifically detects the integrin ␤1 in its active conformation (9EG7), 39, 40 whereas we could not detect VEGFR-3 association with integrin ␤1 on gelatin. In contrast, integrin ␤3 did not associate with VEGFR-3, whereas it associates with VEGFR-2 ( Figure 2C) .
As it was previously demonstrated that integrin ␤1 coimmunoprecipitates with c-Src, 41, 42 we investigate whether VEGFR-3 could be part of a complex with c-Src and integrin ␤1. As shown in Figure 2D , c-Src and VEGFR-3 coimmunoprecipitated with integrin ␤1 suggesting that a VEGFR-3/ Src/integrin␤1 complex is present on the cell surface. Similar results were obtained with the chimeric receptor ( Figure 2E ).
To demonstrate a direct phosphorylation of VEGFR-3 by c-Src we performed by an in vitro kinase. E-R3 was detergent-extracted from transduced HUVECs. The lysates were immunoprecipitated with an anti-VEGFR-3 and anti-Sp3 as a control and immunoprecipitates were subjected to a kinase assay in the presence of recombinant active Src Y527F and ATP. As shown in Figure 2F , kinase dead receptor are direct substrates for Src.
To demonstrate the functional role of Src in VEGFR-3 phosphorylation we performed adhesion assays with cells exposed to PP2, a c-Src kinase inhibitor highly specific if used at low concentration. Cell treatment with PP2 at a final concentration of 1 mol/L did not alter VEGFR-3 autophosphorylation by VEGF-D treatment or E-R3 autophosphory- Table. lation by cell treatment with EGF ( Figure 3A and 3B) . In contrast, 1 mol/L PP2 significantly reduced both VEGFR-3 and E-R3 phosphorylation induced by plating the cells on collagen I-coated dishes ( Figure 3C and 3D; Online Figure  I ). As in adults VEGFR-3 is constitutively expressed in lymphatic vessels, we performed the adhesion experiment also in human lymphatic microvascular endothelial cells (HLMVECs), which express high levels of VEGFR-3 ( Figure  3E ). 43 As shown in Figure 3F , plating HLMVEC on type I collagen induces VEGFR-3 phosphorylation and cell treatment with PP2 significantly reduced VEGFR-3 phosphorylation demonstrating that the crosstalk between VEGFR-3 and integrin ␤1 is a general event.
To further verify the role of c-Src in VEGFR-3 phosphorylation we performed collagen induction in fibroblasts wildtype (SYF ϩ/ϩ ) and "knocked out" for c-Src, Yes, Fyn (SYF Ϫ/Ϫ ) 44 which express integrin ␤1 (Online Figure II) . In SYF Ϫ/Ϫ VEGFR-3 receptor was not phosphorylated on cell adhesion to type I collagen and its phosphorylation was restored by cotransfection of VEGFR-3 with c-Src ( Figure  3G ). Taken together, these results demonstrate that c-Src phosphorylates VEGFR-3 following cell adhesion on type I collagen.
Mapping Src-Dependent Phosphorylation Sites on VEGFR-3
To identify direct Src-target residues we performed in vitro phosphorylation by incubating the recombinant C-terminal domain of the kinase dead VEGFR-3 with active c-Src and searched for tyrosine-phosphorylated residues by mass spectrometric analysis of peptides after trypsin digestion. The phosphorylation sites 830 and 833 contained in the peptide 810 to 842, (m/z 1334.92432) were both detected in the phosphorylated form (Table and Figure 4A and 4B). The phosphorylation site 853 contained in the peptide 850 to 858 (m/z 496.23642) was detected in the phosphorylated form (Table and Figure 4C ). The phosphorylation site 1063 contained in the peptide 1061 to 1070 (m/z 674.30225) was detected in the phosphorylated form (Table and Figure  4D ). The phosphorylation sites 1333 and 1337 contained in the peptide 1328 to 1354 (m/z 1037.75122) were both detected in the phosphorylated form (Table and Figure 4E through 4G).
These results show that c-Src-dependent receptor phosphorylation induces a phosphorylation pattern that is distinct from the phosphorylation pattern induced by the treatment with the growth factor. 35, 45 
Collagen I-Dependent VEGFR-3 Phosphorylation Can Mediate Downstream Signaling
The above results demonstrated that c-Src phosphorylates VEGFR-3 C-terminal domain at several tyrosine residues including 1063 and 1337 previously known to recruit CRKI/II and SHC on receptor phosphorylation. 35, 46 Incubation of the in vitro phosphorylated receptor with the fusion adaptor proteins GST-SH2-CRK or GST-PTB-SHC suggests that c-Src phosphorylation of VEGFR-3 at these tyrosine residues may induce the recruitment of CRKI/II and SHC to the receptor ( Figure 5A ). Pull-down experiments in vivo demonstrated that after adhesion to collagen the chimeric E-R3 KD was able to recruit both CRKI/II and SHC adaptor proteins ( Figure 5B and Online Figure I) . In contrast, the wild-type receptor, but not the kinaseinactive mutant, could bind these adaptor proteins in a ligand-dependent manner. These experiments indicate that the tyrosine residues 1063 and 1337, phosphorylated on cell adhesion to the ECM, independently from activation of the receptor kinase activity, can recruit CRKI/II and SHC adaptor proteins to the receptor and suggest that VEGFR-3 phosphorylation by c-Src contributes to activate receptor downstream signaling.
The functional significance of VEGFR-3 transactivation by cell adhesion was analyzed by in vitro sprouting thus the formation of tube-like structures resembling early capillaries in a 3D type I collagen matrix. HUVECs transduced with either the wild-type or the kinase dead receptor showed a significant increase of the sprouting activity on the collagen matrix, whereas the Y1063F or the Y1337F mutant receptors did not show an increased sprouting with respect to the mock infected cells ( Figure 6B and 6C) .
Analysis of downstream second messengers revealed an increase of JNK phosphorylation on cell induction by type I collagen both with wild-type and kinase dead receptor, whereas JNK phosphorylation was impaired with either Y1063F or Y1337F mutant ( Figure 6D and 6E) .
Furthermore, to evaluate which angiogenic functions were mediated by VEGFR-3 induced by type I collagen we performed cell proliferation, adhesion, migration and apoptosis tests in control (shGFP) and in VERGFR-3 (shR3-D and shR3-F) silenced HUVECs (Figure 7 ). VEGFR-3 silencing significantly affected endothelial cell migration on type I collagen, which is a ligand for the integrin ␤1, whereas it did not affect HUVEC migration on vitronectin, which is a ligand for integrin ␤3 (Figure 7B ). VEGFR-3 silencing also induced increase of apoptosis only on type I collagen ( Figure 7C ), whereas it did not affect cell proliferation measured by DNA synthesis and cell adhesion ( Figure 7D and 7E ).
Discussion
Macromolecular complexes of integrins and growth factor receptors have been documented to cooperate for the optimal response to cognate growth factors and the propagation of downstream signaling. This cooperation has been demonstrated to be crucial for the angiogenic process. 20, 21 We now observed that adhesion-dependent phosphorylation of the receptor VEGFR-3 triggered by the formation of the complex between VEGFR-3 and integrin ␤1 induces the phosphorylation of the receptor independently from the intrinsic kinase activity of the receptor. These results show a remarkable difference from the behavior of VEGFR-2 which is positively regulated by plating cells on vitronectin, whereas type I collagen inhibits VEGFR-2 activation by TCPTP-dependent receptor dephosphorylation. 26, 47, 48 It has been recently shown that VEGFR-3 is specifically expressed in tip cells during sprouting angiogenesis where it plays a role in sprouting, vascular density, and vessel branching. 31, 49 Our results suggest that during the angiogenic process the interactions of sprouting endothelial cells with the ECM, modulating VEGFR-3 signaling, contribute to determine the correct shape of the vascular network.
The activation of VEGFR-3 by the formation of the receptor integrin complex differs from EGF receptor because in the latter case, integrin-dependent adhesion triggers the receptor autophosphorylation, 16 whereas we observed VEGFR-3 phosphorylation independently of intrinsic receptor kinase activity and mediated by c-Src following adhesion. In fact, we observed that VEGFR-3 is a direct target of c-Src that phosphorylates the C-terminal domain of VEGFR-3 at several residues including those critical for the activation of downstream signaling. It was previously shown that c-Src plays a role also in the signaling of VEGFR-2. In this case, on VEGF treatment, c-Src regulates the formation of the complex between VEGFR-2 and ␣v␤3 by phosphorylating the cytoplasmic tyrosine residues of integrin ␤3 inducing structural changes on the complex that promote capillary formation and chemotaxis. 24, 25 Because cell adhesion-dependent receptor phosphorylation could be dissociated from the receptor kinase activity, we were able to identify the tyrosine residues specifically dependent from the integrin/Src-mediated activation by mass spectrometric analysis. This analysis revealed 6 tyrosine residues on VEGFR-3 C-terminal domain, namely tyrosine 830, 833, 853, 1063, 1333, and 1337 demonstrating that integrin-mediated receptor phosphorylation induces a phosphorylation pattern that is distinct from that induced by growth factors.
Functional assays in 3D collagen matrix suggest that adhesion per se could activate a signaling pathway using VEGFR-3 as a scaffold module to activate a downstream signal. c-Src-dependent VEGFR-3 phosphorylation includes tyrosine residues 1063 and 1337, which are docking sites for CRKI/II and SHC, respectively. Our experiments demon-strate that on cell adhesion, and in absence of the intrinsic kinase activity of the receptor, these 2 sites do recruit CRKI/II and SHC adaptor proteins suggesting that cell adhesion contributes to the survival and migration of endothelial cells in agreement with our previous observations. 35 Thus, the ability of integrins to transactivate VEGFR-3 suggests that activation of growth factor receptors in the absence of their specific ligands can be a mechanism of adhesion-mediated signaling. This could play a role during the sprouting process of angiogenesis because endothelial cells, expressing VEGFR-3, get in contact with the ECM and the engagement of integrin in cell matrix interactions may activate a cell response even in the absence or at low doses of the cognate growth factor. Finally, the integrin-mediated VEGFR-3 activation may have implications in medicine because we showed that blocking the receptor with a specific drug is not sufficient to switch off the signaling derived from the receptor. 
